Seeking Alpha

German Merck hints at M&A across divisions

  • "Considering its recent past, any progress would be an improvement," FierceBiotech's Damian Garde writes, referring to comments made by Merck KGaA (MKGAF) CEO Karl-Ludwig Kley which seem to indicate that the German drugmaker is open to acquisitions across its four business units.
  • "We have four sustainable business divisions that are set to grow organically, but for all four areas we have ideas for steps that go beyond that," Kley tells the media.
  • Garde notes that "repeated clinical failures" have left analysts jaded, but innovative ideas like development program cost-sharing could brighten the Erbitux maker's outlook even in the midst of "an R&D diet."
  • See also: German Merck lifts guidance.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs